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Abstract
Background: To investigate if single nucleotide polymorphisms on chromosome 12p13 and within 11 kb of the
gene NINJ2 would be associated with earlier-onset (vs. late-onset) first-ever ischemic stroke and increase silent
cerebrovascular lesions prior to the manifestation of the stroke.
Methods: We prospectively enrolled 164 patients (67.6 ± 12.9 years, 92 men) admitted with first-ever ischemic
strokes. All patients underwent genotyping of rs11833579 and rs12425791 as well as systemic investigations
including magnetic resonance (MR) imaging and other vascular workup. Stroke-related MR lesions were registered
on a brain-template-set using a custom-built software package ‘Image_QNA’: high-signal-intensity ischemic lesions
on diffusion, T2-weighted, or fluid attenuation inversion recovery (FLAIR) MR images, and low signal intensity
hemorrhagic lesions on gradient-echo MR images.
Results: The rs11833579 A/A or G/A genotype was independently associated with the first-ever ischemic stroke
before the age 59 vs. 59 or over, after adjusting for cardiovascular risk factors and prior medication of antiplatelet
or anticoagulant drugs, increasing the risk by about 2.5 fold. In the quantitative MR lesion maps from age-sex
matched subgroups (n = 124 or 126), there was no difference between the patients with the rs11833579 A/A or G/
A genotype and those with the G/G genotype. Unexpectedly, the extent of leukoaraiosis on FLAIR-MR images
tended to be smaller in the corona radiata and centrum semiovale of the patients with the rs12425791 A/A or G/A
genotype than in those with the G/G genotype (P = 0.052). Neither the rs11833579 nor the rs12425791 genotype
significantly affected initial stroke severity; however the latter was associated with relatively low modified Rankin
scale scores at 1 year after stroke.
Conclusions: The rs11833579 A/A or G/A genotype may bring forward the onset age of first-ever ischemic stroke
without increasing silent cerebrovascular lesions prior to the stroke. Further studies are required to confirm our
preliminary findings.
Background
Ischemic Stroke is a leading cause of death and disabil-
ity worldwide. The South London Stroke Register, a
population based study of stroke incidence and out-
come, showed that only a third of survivors had
returned to paid work at 1 year [1]. According to the
results to estimate projected costs of ischemic stroke in
the United States, loss of earnings was expected to be
the highest contributor to the future economic burden
of stroke, constituting nearly one-third of the total costs
[2]. This burden is multiplied if the stroke occurs earlier
in life. The prediction of the stroke onset age would
contribute to better prevention of stroke by allowing
more individualized strategies such as control of modifi-
able vascular risk factors in a more precise and intense
manner. However, there is limited information on fac-
tors influencing the onset age of first-ever ischemic
stroke.
Recently, intergenic single-nucleotide polymorphisms
(rs11833579 or rs12425791 SNP) on chromosome 12p13
a n dw i t h i n1 1k bo ft h eg e n eNINJ2 that encodes nin-
jurin2, an adhesion molecule expressed in glia and
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any medium, provided the original work is properly cited.shows increased expression after nerve injury [3,4], were
reported to be associated with total, ischemic, and ather-
othrombotic stroke in white persons [5]. Thereafter, it
was followed by controversial results in different popula-
tions [6-9]. In the Japanese population, rs12425791 was
significantly associated with atherothrombotic stroke:
both small artery occlusion and large artery athero-
sclerosis [6]. However, many studies including a Chinese
Han study failed to replicate the association of either
rs11833579 or rs12425791with ischemic stroke [7-9]. In
the field of stroke, including the NINJ2-related studies,
failure to find replicated SNP effects across population-
based studies has significantly limited the utility of
genetic association results [10]. Stroke cannot be
regarded as a single disease entity but as a heteroge-
neous syndrome, with more than 150 known causes
[11], under multiple genetic and clinical influences; and
the effect size of a single SNP could be rather small in
predicting stroke risk in the general population. More-
over, roles for a genetic factor in the general population
vs. stroke population may not be identical. In addition,
the influence of genetic factors might be more pro-
nounced in the younger, before classic cardiovascular
risk factors exert their full influence on the disease,
although the genetic and other risk factors could work
in concert and produce stroke at a later age [12]. Taken
together, these led us to reason that clinical implications
for the NINJ2 SNP, including a potential effect on the
onset age of the first-ever ischemic stroke, need to be
further elucidated ‘within a carefully characterized
stroke population’ in a detailed manner that includes
quantitative analyses of magnetic resonance (MR)
images, by which many of diagnostic and therapeutic
decisions are today guided in clinic. Until now, the
impact of the NINJ2 SNP on stroke-related lesions on
multi-sequence MR images has not been studied.
In the present study, we tried to see if the NINJ2 SNP
(A allele) would be associated with earlier-onset (vs.
late-onset) first-ever ischemic stroke. This study, con-
ducted in a hospital-based stroke cohort, could be
underpowered to detect small effects of the single SNP
on the development of the clinical endpoint [10,13].
Thus, in an effort to corroborate the associations, we
used quantitative data on stroke-related MR lesions [14]
as endophenotypes—subclinical phenotypes that are
heritable traits, revealing the actions of genes predispos-
ing an individual to develop conditions known to
increase the risk of future disease, often having a larger
genetic component than clinical disease endpoints, and
manifesting years before clinical diagnostic criteria for
the disease are met [13]. Considering that unrecognized
or covert brain infarcts and white matter lesions are
linked to increased risk for stroke [15], we investigated
if the NINJ2 A/A or G/A genotype increased silent
cerebrovascular lesions such as leukoaraiosis, asympto-
matic lacunes, or microbleeds prior to the manifestation
of first strokes. Moreover, we studied if the NINJ2 geno-
types affected post-stroke functional outcome at 1 year.
Methods
This study was approved by the institutional review
board of Dongguk University Ilsan Hospital (DUIH).
Patients
Out of 586 consecutive first-ever ischemic stroke
patients admitted to our hospital, a community-based
academic hospital at a suburban city (Goyang) in Seoul
Metropolitan Area, from 2008 February to October
2010, we prospectively enrolled 164 patients (67.6 ±
12.9 years, 92 men) who gave written informed consent
to “DUIH stroke-genetic-study project”.T h e yd i dn o t
have a history of hemorrhagic stroke, either. All patients
underwent systemic investigations including assessment
of ischemic cerebral events, medication history, MR
imaging with MR angiography, carotid duplex ultrasono-
graphy, transthoracic echocardiography, 24 h Holter
monitoring, and other routine admission laboratory
tests. In selected patients, transesophageal echocardio-
graphy or transcranial Doppler bubble study was also
performed. Under a standardized protocol, we prospec-
tively collected demographic data, prior medication his-
tory, and the presence of vascular risk factors including
hypertension, diabetes mellitus, dyslipidemia, heart dis-
ease, and smoking.
Risk factor variables and stroke classification
Hypertension was considered to be present if a subject
had one of the following conditions: repeated blood
pressure readings above 140/90 mmHg at 1 ~ 2 weeks
after stroke onset, a history of hypertension, or use of
antihypertensives. Diabetes mellitus was defined as gly-
cated hemoglobin (HbA1C) ≥ 6.5%, history of diabetes
mellitus, or use of diabetic medication. Dyslipidemia
was defined as total cholesterol ≥ 240 mg/dl, low density
lipoprotein cholesterol ≥ 160 mg/dl, a history of dyslipi-
demia, or use of lipid lowering agents. Heart disease as
potential source of cerebral embolism was considered to
be present if a subject had left atrial or ventricular
thrombus, atrial fibrillation or sick sinus syndrome,
recent myocardial infarction within 1 month, rheuma-
toid mitral or aortic valve disease, bioprosthetic or
mechanical heart valves, chronic myocardial infarction
with low ejection fraction less than 28%, symptomatic
congestive heart failure with ejection fraction less than
30%, dilated cardiomyopathy, aneurysms or akinetic seg-
ments of the left ventricular wall, or nonbacterial
thrombotic endocarditis. Smokers included current smo-
kers or those who had stopped smoking for less than 1
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consensus of three neurologists as follows; large artery
atherosclerosis, small vessel occlusion, cardiac embolism,
and ischemic stroke of undetermined etiology, as
described in Trial of Org 10172 in Acute Stroke Treat-
ment (TOAST) [16].
Genotyping
The genomic DNA of each subject was extracted from
peripheral blood mononuclear cells using a Type G
Genomic DNA Extraction Kit (GeneAll, Seoul, Korea)
according to the manufacturer’s instructions. Genotyp-
ing of rs11833579 or rs12425791 was conducted using
ABI BigDye
® Terminator v3.1 Cycle Sequencing Kits
(Aplied Biosystems, Carlsbad, California); genotyping
primers and representative chromatograms of the NINJ2
SNPs are shown (see Additional file 1: Table S1 and
Additional file 2: Figure S1, respectively). Hardy-Wein-
berg equilibrium tests were conducted to determine
whether individual variants were in equilibrium at each
locus. Linkage disequilibrium (LD), Lewontin’sD ’ (|D’|),
and r
2 between pairs of bi-allelic loci were measured
[17].
Brain MR lesion mapping
All patients have had their MR lesions prospectively seg-
mented and registered on the ch2better brain template
http://www.mccauslandcenter.sc.edu/CRNL/, for which a
custom-built software package Image_QNA [14] was
used. The software stores the shape and size of each
lesion mapped in the standard template coordinate sys-
tem, available for future analysis. The registered data
includes high signal intensity ischemic lesions on diffu-
sion, T2-weighted, or fluid attenuation inversion recov-
ery (FLAIR) MR images, and low signal intensity
hemorrhagic lesions on gradient-echo (GE) MR images.
While blinded to patient identification, a trained
research assistant performed the segmentation and
registration under supervision of an experienced neurol-
ogist who can correct the data as needed after reviewing
every registration output. The Image_QNA-based regis-
tration of MR lesions showed low inter- and intra-user
variability. Groups of subjects could be visually grouped
together by generating lesion accumulation maps, in
which summed images are used to display the visual
information of many subjects on a single image set
[14,18].
Statistical analysis
We dichotomized the age quartiles a priori into the first
quartile (58 and below, earlier-onset group) and the
three highest quartiles combined (59 and above, late-
onset group), based on the minimum retirement pension
age (59) in Korea. Between the groups, we compared the
frequency of the NINJ2 SNP (GA or AA alleles) and
conventional risk factors including hypertension, dia-
betes mellitus, dyslipidemia, heart disease, and smoking.
After considering the relationship between the age/sex
and stroke severity/recovery, we reasoned that age-sex
matching was needed in the analysis to see the relation-
ship between the NINJ2 SNP and stroke severity or
recovery or quantitative MR data.
The Student’s t test was used for comparison of nor-
mally-distributed continuous variables between groups.
Chi-square test was used to compare proportions
between groups. A logistic regression model was used to
test statistical significance of the interaction between the
NINJ2 SNP and conventional risk factors in predicting
the earlier-onset of first-ever ischemic stroke. We also
tried to adjust the results for prior medications. In age-
sex matched samples, multivariate analyses were per-
formed to determine if the NINJ2 SNP was an indepen-
dent predictor for admission NIHSS score or 1 year
mRS score. All statistical analyses were performed using
a software package (SPSS 18.0, Chicago, IL). A value of
P < 0.05 was considered statistically significant.
Results
Lower stroke onset ages in the patients with the
rs11833579 A/A or G/A genotype than in those with the
G/G genotype
Out of 586 first-ever ischemic stroke patients admitted
to our hospital from 2008 February to October 2010,
164 patients who gave informed consent were enrolled.
Between the enrolled patients and non-enrolled patients,
there was no significant difference in age (67.5 ± 12.4
years vs. 68.0 ± 12.2 years), male gender (54.9% vs.
53.6%), and initial NIHSS score (5.0 ± 4.6 vs. 5.3 ± 5.9)
(all P > 0.05). However, dyslipidemia was more frequent
and heart disease was less frequent in the enrolled
group than in the non-enrolled group. The use of statin
was more frequent and the use of antihypertensive
drugs was less frequent in the enrolled group than in
the non-enrolled group. Stroke etiologies were statisti-
cally different between the groups. Premorbid mRS was
higher and 1 year mRS was lower in the enrolled group
than in the non-enrolled group (see Additional file 3:
Table S2).
Minor allele frequencies (MAFs) of rs11833579 and
rs12425791 NINJ2 SNP were 0.19 and 0.06, respectively,
which were slightly lower than MAFs of other ethnici-
ties (see Additional file 4: Table S3) registered in the
International HapMap http://hapmap.ncbi.nlm.nih.gov.
The two SNPs satisfied Hardy-Weinberg equilibrium (P
> 0.05). Genotype frequencies of rs11833579 were 48.2%
(G/G), 43.9%, (G/A) and 7.9% (A/A). Those of
rs12425791 were 60.4% (G/G), 36.0% (G/A), and 3.7%
(A/A). The LD coefficients between the two SNPs were
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2 = 0.484 (P < 0.01), which suggested
that these two SNPs were not linked in the Korean
stroke population.
The ages of the patients with the A allele of
rs11833579 SNP (G/A or A/A genotype; 65.2 ± 13.5
years) were lower than those without (G/G genotype;
69.4 ± 11.4 years, P = 0.032). The ages of the patients
with the A allele of rs12425791 SNP (G/A or A/A geno-
type; 65.5 ± 13.3 year) were lower than those without
(G/G genotype; 68.4 ± 12.2 year), which however did
not reach a statistical significance (P = 0.150). Figure 1
shows the difference of cumulative percentage of stroke-
onset-age between the rs11833579 A/A or G/A geno-
type group and the G/G genotype group; the gap
appears to begin being narrowed around the age of 60.
Around the age of 59, the cumulative frequency of first-
ever stroke is about two-fold higher in the rs11833579
A/A or GA genotype group than in the G/G genotype
group: approximately 40% vs. 20%. Around the age of
7 0 ,t h eg e n e t i cp r e d i s p o s i t i o nt os t r o k es e e m e dt ob e
overwhelmed by the age effect.
More frequent rs11833579 A/A or G/A genotype in the
first-ever ischemic stroke patients aged younger than 59
compared with those aged 59 or older
When the stroke onset age was dichotomized at the first
quartile (= age 59), rs11833579 A/A or G/A genotype
was more frequently found in the earlier-onset group
than in the late-onset group (28/40 vs. 57/124, P =
0.008) (Table 1). Rs12425791 A/A or G/A genotype
showed a similar tendency (21/40 vs. 44/124, P = 0.056).
In addition, male sex and smoking were more frequent
in the earlier-onset group than in the late-onset group.
Diabetes mellitus was non-significantly more frequent
Figure 1 Earlier-onset of first-ever ischemic stroke in the
patients with the rs11833579 G/A or A/A SNP than in those
with the G/G type.
Table 1 Univariable analysis: factors associated with
earlier-onset (< 59 years) vs.late-onset (≥ 59) first-ever
ischemic stroke
Earlier-onset
(n = 40)
Late-onset
(n = 124)
P*
Age 50.2 ± 7.1 72.8 ± 8.4 < 0.001
Sex (male) 34 (85.0%) 56 (45.2%) < 0.001
Rs12425791 genotype (GA or AA) 21 (52.5%) 44 (35.5%) 0.056
Rs11833579 genotype (GA or AA) 28 (70.0%) 57 (46.0%) 0.008
Hypertension 25 (62.5%) 91 (73.4%) 0.188
Diabetes mellitus 15 (37.5%) 53 (42.7%) 0.558
Dyslipidemia 31 (77.5%) 79 (63.7%) 0.107
Heart disease 1 (2.5%) 10 (8.1%) 0.298
†
Smoking 31 (77.5%) 55 (44.4%) < 0.001
Current smoking 30 (75.0%) 50 (41.3%) < 0.001
Prior medication
Antihypertensives 11 (27.5%) 52 (41.9%) 0.103
Antidiabetics 9 (22.5%) 38 (30.6%) < 0.001
Statins 10 (25.0%) 37 (29.8%) 0.556
Antiplatelet 8 (20.0%) 23 (18.5%) 0.838
Warfarin 0 (0.00%) 1 (0.81%) 0.572
Ischemic stroke subtype
‡ 0.401
†
Large artery atherosclerosis 11 (27.5%) 36 (29.0%)
Small vessel occlusion 22 (55.0%) 62 (50.0%)
Cardioembolism 2 (5.0%) 4 (3.2%)
Other determined etiology 1 (2.5%) 0 (0%)
Undetermined etiology 4 (10.0%) 22 (17.7%)
Premorbid mRS 0.6 ± 1.2 1.4 ± 1.8 0.001
Admission NIHSS 3.1 ± 2.4 5.5 ± 5.9 < 0.001
Discharge NIHSS 1.7 ± 2.3 3.5 ± 4.6 0.002
NIHSS (Admission - Discharge) 1.4 ± 2.8 2.0 ± 4.9 0.421
Discharge mRS 1.4 ± 1.3 2.4 ± 1.7 < 0.001
1 year mRS (n = 39 & 117) 0.5 ± 0.8 2.0 ± 1.7 < 0.001
Values are number (percentage) or mean ± standard deviation.
*P for Student’s t test or Chi-square test.
†Fisher’s exact test.
‡TOAST classification
mRS and NIHSS denote modified Rankin scale and NIH stroke scale,
respectively.
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more frequent in the late-onset group than in the ear-
lier-onset group. No significant inter-group difference
was observed in other vascular risk factors and stroke
subtypes. The late-onset group had higher premorbid
mRS scores, more severe strokes, and less favorable out-
comes than the earlier-onset group had.
An independent association of rs11833579 A/A or G/A
genotype and male sex with the first-ever ischemic stroke
before the age 59 vs. age 59 or over
To adjust for conventional stroke risk factors a multi-
variable analysis was performed (Table 2), which showed
that rs11833579 A/A or G/A genotype and male sex
were independently associated with the first-ever
ischemic stroke before the age 59 vs. age 59 or over. In
addition, dyslipidemia was associated with the earlier-
onset stroke, which was marginally significant. When
additionally adjusted for prior medication, either antipla-
telet or warfarin, in another regression analysis,
rs11833579 A/A or G/A genotype and male sex were
again positively associated with the earlier-onset of first-
ever ischemic stroke (see Additional file 5: Table S4).
No significant effect of rs11833579 or rs12425791 SNP on
vascular risk factors, stroke etiologies, and initial stroke
severity
By matching age and sex while blinded to patient identi-
fication, we selected 126 subjects with (n = 63, 68.3 ±
11.7 years, 31 men) or without (n = 63, 68.3 ± 11.0
years, 32 men) rs11833579 A/A or G/A genotype (see
Additional file 6: Table S5). There was no intergroup
difference in the vascular risk factors and distribution of
ischemic stroke subtypes. Statin medication was more
frequent in the rs11833579 A/A or G/A genotype group
than in the G/G genotype group with borderline signifi-
cance (P = 0.052). Admission NIHSS scores were non-
significantly (P = 0.103) lower in the former than in the
latter. However, ‘admission NIHSS - discharge NIHSS’
scores did not show statistical differences between the
groups (P = 0.251). At 1 year follow up, mRS scores did
not differ between the groups, either (P = 0. 649). More-
over, in a conditional logistic regression analysis for the
matched subgroup data, no parameters were signifi-
cantly associated with the rs11833579 A/A or G/A gen-
otype vs. G/G genotype (see Additional file 7: Table S6).
Another multivariable linear regression analysis to adjust
for statin medication and premorbid mRS showed that
not the rs11833579 A/A or G/A genotype but premor-
bid mRS was significantly associated with admission
NIHSS scores (see Additional file 8: Table S7).
Table 2 Multivariable analysis: factors associated with
earlier-onset (< 59 years) vs.late-onset (≥ 59) first-ever
ischemic stroke
Variable Odds ratio (95% C.I.) for
the
earlier-onset first stroke
P
Rs11833579 genotype (GA or
AA)
2.46 (1.06-5.69) 0.036
Male sex 5.73 (1.52-21.61) 0.010
Hypertension 0.50 (0.20-1.23) 0.129
Diabetes mellitus 0.95(0.40-2.24) 0.904
Dyslipidemia 2.51(0.98-6.44) 0.057
Heart disease 0.29(0.03-2.78) 0.283
Smoking 1.34 (0.40-4.49) 0.636
Hosmer-Lemeshow goodness-of-fit test showed c
2 = 11.43 and P = 0.18,
demonstrating a good fitness of the model. C.I. confidence interval.
Table 3 Clinical profiles of age-sex matched patients with
the rs12425791 A/A or G/A genotype vs.GG genotype
Rs12425791 genotype P*
(A/A or G/A)
(n = 62)
(GG)
(n = 62)
Age 68.3 ± 11.7 68.3 ± 11.0 0.994
Sex (male) 35 (56.5%) 34 (54.8%) 0.857
Hypertension 42 (67.7%) 46 (74.2%) 0.429
Diabetes mellitus 24 (38.7%) 24 (38.7%) 1.000
Dyslipidemia 41 (66.1%) 47 (75.8%) 0.235
Heart disease 5 (8.1%) 2 (3.2%) 0.439
†
Smoking 32 (51.6%) 33 (53.2%) 0.857
Current smoking 31 (50.0%) 29 (46.8%) 0.526
Prior medication
Antihypertensives 21 (33.9%) 23 (37.1%) 0.707
Antidiabetics 21 (33.9%) 24 (38.7%) 0.575
Statins 19 (30.6%) 19 (30.6%) 1.000
Antiplatelets 12 (19.4%) 12 (19.4%) 1.000
Warfarin 0 (0.0%) 1 (1.6%) 0.496
†
Ischemic stroke subtype
‡ 1.000
†
Large artery atherosclerosis 16 (25.8%) 17 (27.4%)
Small vessel occlusion 35 (56.5%) 35 (56.5%)
Cardioembolism 1 (1.6%) 2 (3.2%)
Other determined etiology 1 (1.6%) 0 (0.0%)
Undetermined etiology 9 (14.5%) 8 (12.9%)
Premorbid mRS 1.2 ± 1.6 1.0 ± 1.6 0.575
Admission NIHSS 4.4 ± 3.6 4.5 ± 4.1 0.872
Discharge NIHSS 2.7 ± 3.7 2.4 ± 2.9 0.629
NIHSS (admission - discharge) 1.7 ± 3.3 2.1 ± 3.5 0.512
Discharge mRS 2.1 ± 1.6 2.0 ± 1.6 0.612
1 year mRS (n = 58 & 62) 1.2 ± 1.4 1.6 ± 1.6 0.143
Values are number (percentage) or mean ± standard deviation.
*P for Student’s t test or Chi-square test.
†Fisher’s exact test.
‡TOAST classification
mRS and NIHSS denote modified Rankin scale and NIH stroke scale,
respectively.
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62, 66.6 ± 12.0 years, 35 men) or without (n = 62, 66.6 ±
11.1 years, 34 men) the rs12425791 A/A or G/A genotype
(Table 3). Between the groups, there was no difference
except that 1 year mRS scores were non-significantly (P =
0.143) lower in the rs12425791 A/A or G/A genotype
group than in the G/G genotype group. In a multivariable
analysis after adjusting for premorbid mRS and admission
NIHSS that turned out to be a significant predictor (P <
0.001) for the mRS score at 1 year, rs12425791 GA or AA
genotype was a significant negative predictor of mRS score
at 1 year (Model I of Table 4).
A trend of smaller white matter lesion extent in the
patients with the rs12425791 A/A or G/A genotype than
in those with the G/G genotype
In the quantitative mapping of stroke-related lesions on
diffusion/FLAIR/T2/GE MR images, there was no differ-
ence between the age-sex matched patients with the
rs11833579 A/A or G/A genotype and those with the G/
G genotype (Figure 2A). Likewise, there was no differ-
ence in the MR images of the age-sex matched patients
with the rs12425791 A/A or G/A genotype vs. those with
the G/G genotype, except that the extent of leukoaraiosis
in the corona radiata and centrum semiovale tended to
be smaller in the former (1861 ± 2437 pixels) than in the
latter (1136 ± 1528 pixels, P = 0.052) (Figure 2B).
When the extent of leukoaraiosis and onset age of
stroke, two parameters that could have potential links
with the NINJ2 SNP or post-stroke prognosis, were
additionally entered into the multivariable analysis
model to predict mRS at 1 year (Model I of Table 4),
the SNP lost significance whereas the age was a statisti-
cally significant predictor and the leukoaraiosis burden
was a marginally significant predictor for the follow-up
mRS (Model II of table 4).
Discussion and Conclusions
In the present study, we found that the rs11833579 A/A
or G/A NINJ2 genotype was an independent risk factor
for the first-ever ischemic stroke before the age 59 vs.
age 59 or over, increasing the relative risk by about 2.5
fold. First strokes occurred before the age 59 in 70% of
the patients with the A/A or G/A genotype, but only in
about 46% of the patients with the G/G genotype. Male
sex was another risk factor for the earlier-onset of first
stroke, which is in line with a previous report [19-22].
In the quantitative mapping of stroke-related lesions on
multi-sequence MR images from age-sex matched sub-
jects, there was no difference between the patients with
the rs11833579 A/A or G/A genotype and those with
the G/G genotype. Both the rs11833579 and rs12425791
genotypes did not significantly affect initial stroke sever-
ity or subsequent recovery from the stroke.
Meschia et al. reported that family history of stroke
before the age of 65 years was a stronger risk factor at
age 65 years or earlier, which indicates that an inherited
component of stroke risk may attenuate with age
[23-25]. Thus, once risk factor genes are identified, it
would be informative to assess relative risk for stroke as
a function of age [26,27]. We found that around the age
s i x t yt h eg e n e t i cp r e d i s p o s i t i o nt os t r o k eb yt h e
rs11833579 A/A or G/A genotype started being attenu-
ated by the age effect. After adjusting for conventional
risk factors and prior medication of antiplatelet or antic-
oagulant drugs, the association between the rs11833579
A/A or G/A genotype and the earlier-onset of first
ischemic stroke remained significant. Between the age-
sex matched subgroups with vs. without the rs11833579
A/A or G/A genotype, there was no difference in the
extent and distribution of silent cerebrovascular lesions
as well as of acute ischemic infarction. In addition, there
was no intergroup difference in the vascular risk factors
Table 4 Multivariable analyses to predict modified Rankin scale (mRS) score at 1 year
Variable Odds ratio (95% C.I.) for mRS score P
Model I
Rs12425791 (GA or AA) -0.15 (-1.01-0.04) 0.036
Premorbid mRS 0.09 (-0.07-0.24) 0.262
Admission NIHSS 0.38 (0.08-0.20) < 0.001
Model II
Rs12425791 (GA or AA) -0.080 (-0.618-0.150) 0.230
Premorbid mRS 0.016 (-0.122-0.152) 0.825
Admission NIHSS 0.323 (0.068-0.171) < 0.001
Age 0.369 (0.030-0.067) < 0.001
Pre-stroke leukoraiosis burden (per 100 pixels) 0.128 (0.000-0.016) 0.068
NIHSS and C.I. denote NIH stroke scale and confidence interval, respectively.
Leukoaraiosis burden: extent of leukoaraiosis in the corona radiata and centrum semiovale on fluid attenuation inversion recovery (FLAIR) magnetic resonance
images
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explain the results that initial stroke severity or subse-
quent recovery from the stroke did not differ between
the groups.
The Framingham Heart Study showed that the pre-
sence of severe leukoaraiosis at baseline more than dou-
bles the future risk of stroke [28]. Many studies showed
that leukoaraiosis volume, influenced by genetic
Figure 2 Accumulation MR lesion maps depending on the rs11833579 (A) or rs12425791 (B) genotype. Quantitative maps of diffusion/
fluid attenuation inversion recovery (FLAIR)/T2/gradient-echo (GE) MR images show no significant difference between the age-sex matched
patients with the rs11833579 A/A or G/A genotype and those with the G/G genotype (A). In the age-sex matched patients with the rs12425791
A/A or G/A genotype (B), compared with the ones with the G/G genotype, the extent of leukoaraiosis in the centrum semiovale (first row) and
corona radiata (second row) on FLAIR MRIs appears to be smaller. The pseudocolor bars indicate numbers of subjects with lesions overlapping a
specific pixel.
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highly heritable [29-31]. In our study, the burden of leu-
koaraiosis did not differ between the patients with the
rs11833579 A/A or G/A genotype and those with the
G/G genotype. The mean onset age of first-ever
ischemic stroke was significantly but modestly (about 4
years) younger in the patients with the A allele than in
those without. These suggest that the genetic factor
might work in concert with other classic risk factors
[12,32] that do not affect leukoaraiosis, or induce stroke
before the conventional vascular risk factors exert their
full influence on the leukoaraiosis. It should be under-
stood in a similar vein that NINJ2 SNPs were not asso-
ciated with an increased risk of the other covet
cerebrovascular lesions—clinically silent infarcts or
hemorrhage—either.
We found a trend of earlier-onset stroke in the
patients with the rs12425791 A/A or G/A genotype
compared with those with the G/G genotype; however,
the extent of leukoaraiosis in the corona radiata and
centrum semiovale tended to be smaller in the age-sex
matched patients with the A/A or G/A genotype than in
those with the G/G genotype. The weak association of
the SNP with lower leukoaraio i sb u r d e na sw e l la sw i t h
earlier-onset stroke should be further investigated in
future research. The association might be a mere coinci-
dence, however it again suggests that aggravation of
small vessel disease may not be the cause of the SNP-
associated earlier-onset of first-ever ischemic stroke.
The Greater Cincinnati Stroke Study [33] and a single
center study from Massachusetts General Hospital [34]
showed that, when compared with no or mild leukoar-
aiosis, severe leukoaraiosis was a strong predictor of a
higher mRS score at 3 or 6 months. Thus, the
rs12425791 A/A or G/A genotype-related attenuation of
leukoaraisosis, along with the non-significantly earlier
onset of the first stroke, might have contributed to rela-
tively low post-stroke mRS scores at 1 year. This may
be supported by the results of the two-step multivariable
analysis (Table 4), which showed that the NINJ2 SNP
lost significance after entering the ‘extent of leukoaraio-
sis’ and ‘onset age of stroke’ into the model.
There have been conflicting reports on the association
between the NINJ2 SNP and ischemic stroke [5-8]. This
may be due to heterogeneity among different ethnic
groups or false positive or false negative results, possibly
being related to the small effect size of the SNP in
terms of predicting the stroke risk in the general popu-
lation. The present study conducted within Korean
stroke patients, while having characterized the subjects
in a detailed manner with prospective registration of not
only alphanumeric data but also a comprehensive set of
quantitative multi-sequence MR imaging data [14], may
have selection bias; and, our findings need to be
replicated in other population samples. In addition, our
short-term cohort study did not investigate the duration
of exposure to cardiovascularr i s kf a c t o r s ,q u a l i t yo f
control of the risk factors, and environmental factors
that could influence the onset age of first stroke. Despite
the limitations, as a hypothesis-generating research, our
study to provide with both genetic and quantitative-MR
data as well as post-stroke functional outcome data mer-
its further confirmatory investigation with a larger sam-
ple size.
To summarize, the rs11833579 A/A or G/A NINJ2
genotype may bring forward the onset age of first-ever
ischemic stroke without affecting asymptomatic cerebro-
vascular lesion formation prior to the stroke and neuro-
logical and radiological severity of the stroke, and
functional recovery after the stroke. The rs12425791 A/
A or G/A genotype was associated with relatively low
post-stroke mRS scores at 1 year.
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